SEC Form 8-K Summary
Registrant: MedTech Acquisition Corporation (proposed to be renamed TriSalus Life Sciences, Inc. upon completion of the Business Combination)
Reporting date: March 4, 2023; filed March 8, 2023.
Business Context and Transaction
MedTech Acquisition Corporation (MTAC) reported an amendment to the November 11, 2022 non-binding term sheet with TriSalus Life Sciences, Inc. and Magnetar Capital LLC. The parties are pursuing a merger in which MTAC’s wholly owned subsidiary would merge with TriSalus, with TriSalus surviving as a wholly owned subsidiary of MTAC. TriSalus equity holders would receive MTAC common stock.
The proposed Business Combination remains subject to specified conditions, including stockholder approval, regulatory approvals, satisfaction of minimum cash requirements after redemptions, and other closing conditions. MTAC stated that its Form S-4 registration statement was not yet effective as of the filing date.
Material Agreement Amendment
- The parties’ term sheet contemplates the issuance of up to $50 million of 8.0% senior secured convertible notes by MTAC in connection with the Business Combination.
- The March 4, 2023 amendment increased the cap on reimbursement of Magnetar’s transaction-related expenses from $300,000 to $600,000.
- The filing does not provide information on whether the contemplated convertible notes had been issued or funded.
Financial Metrics and Liquidity
This Form 8-K does not report revenue, profit or loss, cash flow, margins, debt balances, cash balances, liquidity ratios, or other operating financial metrics. It also does not provide a new financial outlook or guidance.
Outlook, Risks, and Contingencies
Management included forward-looking statements regarding the Business Combination and potential additional financing. The transaction may not close on time or at all, and could fail if approval, minimum-cash, regulatory, listing, or other conditions are not satisfied.
Additional disclosed risks include stockholder redemptions, termination of the Merger Agreement, competing proposals, litigation, Nasdaq delisting, financing needs, reimbursement changes, clinical and regulatory failure of TriSalus product candidates, the ability to grow TriNav sales, continued funding of SD-101 trials, commercialization and market-size uncertainty, competition, growth execution, and failure to realize anticipated transaction benefits.
The filing cautions that forward-looking statements are subject to substantial risks and that neither MTAC nor TriSalus undertakes to update them.
Most Important Facts to Verify
- Whether the Form S-4 registration statement becomes effective and the definitive proxy statement/prospectus is filed.
- Whether MTAC stockholders approve the Business Combination and the number of shares ultimately redeemed.
- Whether the minimum cash condition and other closing conditions are satisfied.
- Whether the contemplated 8.0% senior secured convertible notes are issued, including final principal amount and terms.
- Whether Magnetar’s expense reimbursement reaches the amended cap of $600,000.
- Whether the Business Combination closes and MTAC is renamed TriSalus Life Sciences, Inc.